Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets

E-ISSN： 2212-3873|6|4|305-311

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.6, Iss.4, 2006-12, pp. : 305-311

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Molecular Targets for Systemic Lupus Erythematosus

Current Drug Targets, Vol. 3, Iss. 3, 2002-06 ,pp. : 223-228

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic potential of IL-27 in systemic lupus erythematosus

By Pan Hai-Feng Tao Jin-Hui Ye Dong-Qing

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 5, 2010-05 ,pp. : 479-484

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Targets of Misguided T Cells in Systemic Lupus Erythematosus

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 3, 2005-06 ,pp. : 295-298

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacotherapy of systemic lupus erythematosus

By Francis Lisa Perl Andras

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 9, 2009-06 ,pp. : 1481-1494

Informa Healthcare

Access to resources Recommend Favorite

Belimumab: In Systemic Lupus Erythematosus

By Burness Celeste B. McCormack Paul L.

Drugs, Vol. 71, Iss. 18, 2011-12 ,pp. : 2435-2444

Adis International

Access to resources Recommend Favorite